Cardiff Oncology (CRDF) Plunges 31.97% Amid Leadership Shakeup and Mixed Trial Data Skepticism

Cardiff Oncology Inc. (CRDF) fell to its lowest level since February 2024 on Jan. 29, with an intraday decline of 37.07% before closing down 31.97%.

The selloff followed the resignation of CEO Dr. Mark Erlander and CFO James Levine, triggering an interim leadership transition and mixed reactions to Phase 2 trial data for its lead candidate, onvansertib. The drug showed a 72.2% confirmed objective response rate in a 30 mg dose for RAS-mutated metastatic colorectal cancer but failed to meet investor expectations for statistical significance or clear regulatory pathways. The stock plummeted nearly 30% in pre-market trading, reflecting skepticism about the data’s robustness and the company’s ability to secure FDA approval.

Despite positive signals, the stock’s sharp drop reflected skepticism about operational stability under interim CEO Dr. Mani Mohindru and concerns over cash burn amid late-stage trial plans. The board’s focus on a high-impact indication underscores the drug’s potential but hinges on FDA approval and execution risks that remain critical for investor confidence. The leadership changes and financial pressures highlight the challenges facing Cardiff as it navigates late-stage development and seeks to stabilize its leadership structure.